Genome‐wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma

In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genome‐wide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA.

[1]  David T. W. Jones,et al.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.

[2]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[3]  T. Maehara,et al.  Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma , 2017, Acta Neuropathologica.

[4]  S. Patil,et al.  Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas—Same Entity or First Cousins? , 2016, Brain pathology.

[5]  David T. W. Jones,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[6]  P. Burger,et al.  Pleomorphic Xanthoastrocytoma: Natural History and Long‐Term Follow‐Up , 2015, Brain pathology.

[7]  K. Ogawa,et al.  Distinctive expression and function of four GSDM family genes (GSDMA‐D) in normal and malignant upper gastrointestinal epithelium , 2009, Genes, chromosomes & cancer.

[8]  A. Feletti,et al.  Malignant progression in pleomorphic xanthoastrocytoma: Personal experience and review of the literature , 2007, Journal of the Neurological Sciences.

[9]  David T. W. Jones,et al.  BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Louis WHO classification of tumours of the central nervous system , 2007 .